Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
PT Kalbe Farma Tbk.
Kalbe makes and sells medicines, vitamins, nutritional drinks, and health products for people in Indonesia and beyond.
Kalbe is Indonesia's biggest drug company. It makes the pills your doctor prescribes, the vitamins and supplements in your bathroom cabinet, and the nutritional drinks sold in shops and given to patients in hospitals. Walk into almost any pharmacy or supermarket in Indonesia and you'll find its brands — products like Promag for stomach aches, Mixagrip for colds, and Hydro Coco coconut water for hydration. It also makes prescription medicines and sterile injectable drugs for hospitals, and sells health products abroad.
The business splits into a few moving parts. The biggest is prescription pharmaceuticals — medicines sold under the company's own name to doctors and hospitals. Then there's consumer health, the over-the-counter pills and supplements ordinary people buy themselves. There's also nutritionals: powdered milk and drinks for children, pregnant women, and the elderly. Kalbe also runs distribution, moving its own products and other companies' goods through a huge network of warehouses and salespeople across Indonesia's thousands of islands. That logistics muscle is a quiet advantage, because getting a box of medicine to a small town in Sulawesi is a real headache most rivals would rather not handle. Kalbe earns its money because doctors trust the brands, because its distribution reaches places competitors can't, and because Indonesia is a country of more than 270 million people with a growing middle class and a government pushing to expand healthcare coverage. If more people can afford to see a doctor and get a prescription, Kalbe wins.
The company spent decades expanding, buying factories, and building its own research labs. One thing Kalbe does with its cash is pay a steady dividend and reinvest in capacity. It's not a flashy story — nobody gets excited about a company that sells stomach medicine — but it's the kind of steady, cash-generating business that tends to quietly compound for a long time. The main risk is the same as any drugmaker's: prices in Indonesia get squeezed by government policy, and a cheap local rival or a big multinational can eat into its turf.
Saved answer · last researched 12 Nov 2026